君百延集團(08372.HK)年度收益同比增加約15.3%至9440萬港元
格隆匯6月20日丨君百延集團(08372.HK)公告,集團收益由截至2024年3月31日止年度約8190萬港元增加約15.3%至截至2025年3月31日止年度約9440萬港元。有關增加主要由於年內集團就香港特別行政區政府所實施的《第一個醫院發展計劃》下現有醫院擴建的醫療設備供應進行若幹投標中標所致。集團溢利由截至2024年3月31日止年度約780萬港元增加約140萬港元至截至2025年3月31日止年度約920萬港元。有關增加主要由於收益增加以及上文所闡釋的行政及其他經營開支增加幅度較少所致。
董事會宣派截至2025年3月31日止年度中期股息每股普通股0.25港仙(2024年:0.25港仙)取代末期股息。預期中期股息將於2025年8月11日(星期一)或前派付予於2025年7月18日(星期五)名列股東名冊的本公司股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.